Nouscom, an immuno-oncology company developing off-the-shelf and personalized neoantigen-based genetic cancer vaccines based on its clinically validated Exovax platform, announced the appointment of Adrian Woolfson M.D., Ph.D. as Chief Medical Officer (CMO).
Dr. Woolfson brings to Nouscom over a decade of extensive and broad experience in leading clinical trials in oncology and hematology in the pharmaceutical industry. At Nouscom Dr. Woolfson will play a key role in leading the Company’s clinical development of its neoantigen off-the-shelf vaccine targeting tumors associated with Microsatellite Instability (MSI), as well as the personalized neoantigen vaccines and oncolytic virus programs.
“Nouscom is positioned to be a leading player in the neoantigen vaccine space. The Company combines a deep knowledge of infectious disease vaccines, with cutting-edge neoantigen predictive bioinformatics, a proprietary best-in-class platform, and a state-of-the art manufacturing capability,” said Dr. Adrian Woolfson. “I look forward to working with Nouscom’s highly experienced management team to develop its innovative neoantigen-based genetic cancer vaccines and potentially make this treatment option available to physicians and cancer patients.”
Dr. Woolfson joins Nouscom from Pfizer where he most recently served as Global Clinical Leader Early and Late Stage Immuno-Oncology/Hematology and was responsible for building a diverse portfolio of monotherapy and combination studies for Pfizer’s PD-L1 inhibitor Bavencio and 4-1BB agonist Utomilumab. Prior to Pfizer, he was Global Clinical Lead at Bristol-Myers Squibb where he was responsible for the development of a portfolio of small-molecule inhibitors including JAK2, CDC7, SMO, and IGF-1R/IR.
Nouscom AG, based in Basel, Switzerland, develops a technology platform that is based on tumor targeted oncolytic viruses and patient-specific cancer vaccines. The company offers Endovax antigenless vaccine that encodes immunomodulators, breaks tolerance, and primes/rescues cancer-specific immune response; and Exovax personalized vaccine that encodes neoantigens and boosts cancer-specific responses for sustained immunity. Its technology is based on viral vectors and oncolytic viruses.